中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2013年
5期
341-344
,共4页
孟庆雯%李勇%胡宝山%邵培坚%占美晓%禹娴怡%陆骊工
孟慶雯%李勇%鬍寶山%邵培堅%佔美曉%禹嫻怡%陸驪工
맹경문%리용%호보산%소배견%점미효%우한이%륙려공
癌,肝细胞%药物疗法,联合%血管内皮生长因子受体2
癌,肝細胞%藥物療法,聯閤%血管內皮生長因子受體2
암,간세포%약물요법,연합%혈관내피생장인자수체2
Carcinoma,hepatocellular%Drug therapy,combination%Vascular endothelial growth factor receptor-2
目的 探讨血清血管内皮生长因子受体-2(VEGFR-2)在预测行肝动脉栓塞化疗(TACE)的原发性肝癌患者(HCC)预后中的作用.方法 选取2008年10月至2012年4月广东省人民医院介入科行TACE治疗的69例HCC患者,采用酶联免疫吸附实验(ELISA)方法检测行TACE术前及术后患者血清VEGFR-2浓度；分析血清VEGFR-2浓度与临床病理特征和预后的关系.结果 血清VEGFR-2浓度在有无肝硬化组及肿瘤数目分组差异有统计学意义(P =0.021,P=0.049),与其他临床基线资料差异未发现有统计学意义；HCC患者行TACE术后[(10558 ±7007) ng/L]和术前[(8709 ±6510) ng/L]血清VEGFR-2浓度差异有统计学意义(P =0.045)；按术前血清VEGFR-2浓度平均数8709 ng/L分组,术前血清VEGFR-2高浓度的HCC患者其总生存时间及无疾病进展时间短于血清VEGFR-2低浓度的患者(17个月比28个月,P=0.001；10个月比15个月,P=0.031).Cox回归示术前血清VEGFR-2浓度是独立预后因素.结论 术前血清VEGFR-2浓度可以预测行TACE的HCC患者的预后.
目的 探討血清血管內皮生長因子受體-2(VEGFR-2)在預測行肝動脈栓塞化療(TACE)的原髮性肝癌患者(HCC)預後中的作用.方法 選取2008年10月至2012年4月廣東省人民醫院介入科行TACE治療的69例HCC患者,採用酶聯免疫吸附實驗(ELISA)方法檢測行TACE術前及術後患者血清VEGFR-2濃度；分析血清VEGFR-2濃度與臨床病理特徵和預後的關繫.結果 血清VEGFR-2濃度在有無肝硬化組及腫瘤數目分組差異有統計學意義(P =0.021,P=0.049),與其他臨床基線資料差異未髮現有統計學意義；HCC患者行TACE術後[(10558 ±7007) ng/L]和術前[(8709 ±6510) ng/L]血清VEGFR-2濃度差異有統計學意義(P =0.045)；按術前血清VEGFR-2濃度平均數8709 ng/L分組,術前血清VEGFR-2高濃度的HCC患者其總生存時間及無疾病進展時間短于血清VEGFR-2低濃度的患者(17箇月比28箇月,P=0.001；10箇月比15箇月,P=0.031).Cox迴歸示術前血清VEGFR-2濃度是獨立預後因素.結論 術前血清VEGFR-2濃度可以預測行TACE的HCC患者的預後.
목적 탐토혈청혈관내피생장인자수체-2(VEGFR-2)재예측행간동맥전새화료(TACE)적원발성간암환자(HCC)예후중적작용.방법 선취2008년10월지2012년4월광동성인민의원개입과행TACE치료적69례HCC환자,채용매련면역흡부실험(ELISA)방법검측행TACE술전급술후환자혈청VEGFR-2농도；분석혈청VEGFR-2농도여림상병리특정화예후적관계.결과 혈청VEGFR-2농도재유무간경화조급종류수목분조차이유통계학의의(P =0.021,P=0.049),여기타림상기선자료차이미발현유통계학의의；HCC환자행TACE술후[(10558 ±7007) ng/L]화술전[(8709 ±6510) ng/L]혈청VEGFR-2농도차이유통계학의의(P =0.045)；안술전혈청VEGFR-2농도평균수8709 ng/L분조,술전혈청VEGFR-2고농도적HCC환자기총생존시간급무질병진전시간단우혈청VEGFR-2저농도적환자(17개월비28개월,P=0.001；10개월비15개월,P=0.031).Cox회귀시술전혈청VEGFR-2농도시독립예후인소.결론 술전혈청VEGFR-2농도가이예측행TACE적HCC환자적예후.
Objective To explore the prognostic significance of serum vascular endothelial growth factor receptor-2 (VEGFR-2) in patients with hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE).Methods A total of 69 HCC patients undergoing TACE from October 2008 to April 2012 were recruited and examined.Their serum level of VEGFR-2 level was measured by enzymelinked immunosorbent assay (ELISA).The relationship between VEGFR-2 and their clinicopathologic features were observed.Prognostic significance of VEGFR-2 was assessed for their survival.Results Significant differences existed when the serum level of VEGFR-2 was categorized by tumor number and liver cirrhosis(P =0.021,P =0.049).The post-treatment serum level of VEGFR-2 was significant higher than that at pre-treatment (P =0.045).When the mean pre-treatment serum level of VEGFR-2 (8709 ng/L) was used as a cut-off point,the patients with a low serum level of VEGFR-2 had better overall and progression-free survival than those with a high serum level of VEGF (17 vs.28 months,P =0.001 and 10 vs.15 months P =0.031 respectively).As revealed by multivariate Cox analysis,the pre-treatment serum level of VEGFR-2 was an independent and significant prognostic factor of survival for HCC patients at postTACE.Conclusion The pre-treatment serum level of VEGFR-2 may predict the post-TACE prognosis in HCC patients.
